SEC Form 4 · accession 0001123292-17-001368
Recro Pharma, Inc. · REPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jyrki Mattila
Officer — Executive VP, Business Dev.
Period of report
Aug 21, 2017
Accepted (ET)
Aug 21, 2017 · 5:56 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001588972
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $6.98 | Aug 21, 2017 | A | 75,000 | A | — | Aug 21, 2027 | Common Stock | 75,000 | 75,000 | D |
| Restricted Stock UnitsF2,F3 | — | Aug 21, 2017 | A | 12,000 | A | — | — | Common Stock | 12,000 | 12,000 | D |
Explanation of responses
- F1The stock option vests in equal monthly installments over 48 months, beginning on the date that is one month from the date of grant, subject to continued employment with the Company. The stock option is an inducement grant under NASDAQ listing rule 5635(c)(4).
- F2Each restricted stock unit represents a contingent right to receive one share of the Company's common stock.
- F3The restricted stock units vest in four equal annual installments beginning August 21, 2018. Vested shares will be delivered to the reporting person within 30 days following each respective vesting date. The restricted stock unit award is an inducement grant under NASDAQ listing rule 5635(c)(4).